Видео ютуба по тегу Biocon Group Ipo

Biocon Biologics CEO: Integration To Boost Value, Balance Sheet & Competitiveness | Business News
Biocon Biologics CEO: Integration To Boost Value, Balance Sheet & Competitiveness | Business News
Biocon Biologics Restructures Deal With SII | Nithya Balasubramanian Speaks On This & More
Biocon Biologics Restructures Deal With SII | Nithya Balasubramanian Speaks On This & More
Spotlight On Biocon-Serum Deal, Ipca's Unichem Acquisitions & Mankind Pharma's IPO | CNBC-TV18
Spotlight On Biocon-Serum Deal, Ipca's Unichem Acquisitions & Mankind Pharma's IPO | CNBC-TV18
Biocon Biosimilars Consolidation Rationale! Eye On Capex Cycle, R&D Costs & Global Play | Business
Biocon Biosimilars Consolidation Rationale! Eye On Capex Cycle, R&D Costs & Global Play | Business
Biocon biologics IPO on the Cards? | Biocon's Kiran Mazumdar Shaw to ET NOW
Biocon biologics IPO on the Cards? | Biocon's Kiran Mazumdar Shaw to ET NOW
Biocon Set For New Biosimilar Launch
Biocon Set For New Biosimilar Launch
Biocon’s Kiran Mazumdar Shaw & Syngene’s Peter Bains On Syngene IPO | EXCL
Biocon’s Kiran Mazumdar Shaw & Syngene’s Peter Bains On Syngene IPO | EXCL
Exclusive | Goldman Sachs Might Acquire Minority Stake In Shaw-led Biocon Biologics
Exclusive | Goldman Sachs Might Acquire Minority Stake In Shaw-led Biocon Biologics
SYNGENE IPO CONFERENCE TODAY
SYNGENE IPO CONFERENCE TODAY
Biocon Biologics To Close Viatris Deal Soon, IPO Plan Likely In 12-24 Months
Biocon Biologics To Close Viatris Deal Soon, IPO Plan Likely In 12-24 Months
There Was A Strong Demand For The QIP From Both Domestic & Foreign Investors: Biocon | CNBC TV18
There Was A Strong Demand For The QIP From Both Domestic & Foreign Investors: Biocon | CNBC TV18
Biocon's Kiran Mazumdar Shaw On Syngene’s IPO
Biocon's Kiran Mazumdar Shaw On Syngene’s IPO
Kiran Mazumdar-Shaw, Chairperson, Biocon Group speaking on Q1 FY26 Results
Kiran Mazumdar-Shaw, Chairperson, Biocon Group speaking on Q1 FY26 Results
Biocon Biologies IPO, Debt Reduction Strategy & More | Kiran Mazumdar-Shaw & Peter Bains
Biocon Biologies IPO, Debt Reduction Strategy & More | Kiran Mazumdar-Shaw & Peter Bains
Reporter's Take | Biocon Biologics raises Rs 530 crore at steep $3 bn valuation
Reporter's Take | Biocon Biologics raises Rs 530 crore at steep $3 bn valuation
Let’s Break It Down: Kiran Mazumdar-Shaw’s $5.5 Billion Biocon Biologics Bet
Let’s Break It Down: Kiran Mazumdar-Shaw’s $5.5 Billion Biocon Biologics Bet
Stocks On Radar: Biocon Viatris Acquisition, Debt Reduction Are Re-Rating Triggers | Macquarie View
Stocks On Radar: Biocon Viatris Acquisition, Debt Reduction Are Re-Rating Triggers | Macquarie View
Ajay Bhardwaj's Anthem Biosciences Makes A Robust IPO Debut: Here's Its Compelling Origin Story!
Ajay Bhardwaj's Anthem Biosciences Makes A Robust IPO Debut: Here's Its Compelling Origin Story!
Biocon Acquires Viatris' Biosimilars Biz: Kiran Mazumdar-Shaw On Deal Rationale & Growth Road Map
Biocon Acquires Viatris' Biosimilars Biz: Kiran Mazumdar-Shaw On Deal Rationale & Growth Road Map
Stocks to Watch: Tata Motors CV Listing, Adani Rights Issue, Biocon Q2 Beat, Vodafone Idea Relief
Stocks to Watch: Tata Motors CV Listing, Adani Rights Issue, Biocon Q2 Beat, Vodafone Idea Relief